Purple Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Cost of Revenue	0.06	0.06	0.2	0.12	0.06	Upgrade
Gross Profit	-0.06	-0.06	-0.2	-0.12	-0.06	Upgrade
Selling, General & Admin	3.19	3.12	5.04	6.16	6.04	Upgrade
Research & Development	3.73	7.62	17.03	16.32	11.83	Upgrade
Operating Expenses	6.92	10.74	22.08	22.48	17.87	Upgrade
Operating Income	-6.98	-10.8	-22.27	-22.6	-17.92	Upgrade
Interest & Investment Income	0.23	0.26	0.47	0.53	0.32	Upgrade
Currency Exchange Gain (Loss)	0.01	-0.01	-0.01	0.06	-0.13	Upgrade
Other Non Operating Income (Expenses)	0.73	3.48	1.83	0.25	-0.08	Upgrade
EBT Excluding Unusual Items	-6.01	-7.08	-19.98	-21.76	-17.81	Upgrade
Asset Writedown	-20.48	-0.2	-	-	-	Upgrade
Legal Settlements	-	-	-	-	-0.01	Upgrade
Pretax Income	-26.49	-7.28	-19.98	-21.76	-17.83	Upgrade
Earnings From Continuing Operations	-26.49	-7.28	-19.98	-21.76	-17.83	Upgrade
Earnings From Discontinued Operations	-	-	-	-	-0.64	Upgrade
Net Income to Company	-26.49	-7.28	-19.98	-21.76	-18.47	Upgrade
Minority Interest in Earnings	0.11	0.04	0.1	0.09	0.08	Upgrade
Net Income	-26.39	-7.24	-19.88	-21.67	-18.38	Upgrade
Net Income to Common	-26.39	-7.24	-19.88	-21.67	-18.38	Upgrade
Shares Outstanding (Basic)	960	328	221	181	176	Upgrade
Shares Outstanding (Diluted)	960	328	221	181	176	Upgrade
Shares Change (YoY)	192.79%	48.15%	22.41%	2.92%	52.76%	Upgrade
EPS (Basic)	-0.03	-0.02	-0.09	-0.12	-0.10	Upgrade
EPS (Diluted)	-0.03	-0.02	-0.09	-0.12	-0.10	Upgrade
Free Cash Flow	-5.66	-14.37	-19.93	-16.76	-15.37	Upgrade
Free Cash Flow Per Share	-0.01	-0.04	-0.09	-0.09	-0.09	Upgrade
EBITDA	-6.97	-10.77	-22.07	-22.4	-17.69	Upgrade
D&A For EBITDA	0	0.03	0.2	0.2	0.23	Upgrade
EBIT	-6.98	-10.8	-22.27	-22.6	-17.92	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.